Fibroblast Activation Protein Inhibitor Theranostics
PET Clinics · 2023-07 · 18 (3) · 419-428
DOI: 10.1016/j.cpet.2023.02.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PET Clinics, 2023-07. Verfasst von Yuriko Mori und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstrasse 5, 40225, D…. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Fibroblast activation protein (FAP)-targeted radioligand therapy offers a possibility of a novel cancer therapeutic strategy, aiming at tumor stroma1. Early clinical translations of FAP-tracers occurred as early as in the 1990s using antibodies, without substantial achievement further than the clinical phase II trial. The essential step toward the theranostic approach, with a conceptual combination of diagnostic and therapeutic emitters in a specific tracer, began with the implementation of small-molecule FAP-enzyme inhibitors (FAPI) in 2018. Currently, FAPI-04 and FAPI-46, containing DOTA-chelators with the possibility of radionuclide combination (Ga-68, Y-90, and Lu-177), are the compounds most widely used in the theranostic regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany. Electronic address: yuriko.mori@med.uni-duesseldo…
- Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
- Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany; Department of Nuclear Medicine, Heidelberg Univer…
Zitieren
APA
Mori, Y., Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2023). Fibroblast Activation Protein Inhibitor Theranostics. PET Clinics, 18(3), 419-428. https://doi.org/10.1016/j.cpet.2023.02.007
Vancouver
Mori Y, Kratochwil C, Haberkorn U, Giesel FL. Fibroblast Activation Protein Inhibitor Theranostics. PET Clinics. 2023;18(3):419-428. doi:10.1016/j.cpet.2023.02.007
BibTeX
@article{Mori2023,
author = {Mori, Yuriko and Kratochwil, Clemens and Haberkorn, Uwe and Giesel, Frederik L},
title = {Fibroblast Activation Protein Inhibitor Theranostics},
journal = {PET Clinics},
year = {2023},
volume = {18},
number = {3},
pages = {419--428},
doi = {10.1016/j.cpet.2023.02.007}
}
EUVIMED